<DOC>
	<DOCNO>NCT00002737</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell slow growth kidney cancer . Isotretinoin may help kidney cancer cell develop normal cell . It yet know whether interferon alfa plus isotretinoin effective interferon alfa alone kidney cancer . PURPOSE : Randomized phase III trial compare effectiveness interferon alfa without isotretinoin treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Interferon Alfa With Without Isotretinoin Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response rate response duration interferon alfa v without isotretinoin patient bidimensionally measurable progressive metastasis renal cell cancer . II . Assess toxic effect regimens patient population . III . Determine overall survival patient population treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . Patients randomize one two treatment arm . Arm I : Patients receive interferon alfa subcutaneously daily . Arm II : Patients receive interferon alfa arm I plus oral isotretinoin daily . Treatment continue 1 year absence disease progression unacceptable toxicity . Patients follow death . PROJECTED ACCRUAL : A total 296 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell adenocarcinoma Histologic confirmation metastasis desirable Progression metastasis within 2 month study No clinically manifest CNS metastasis Bidimensionally measurable metastasis , follow : Lung lesion diameter great 2 cm Superficial lymph node skin subcutaneous lesion diameter great 2.5 cm Lymph node mediastinum retroperitoneal region , liver lesion , soft tissue lesion visible CT ultrasound initial diameter great 2.5 cm No bone lesion without surround , measurable soft tissue lesion PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 0 1 Life expectancy : At least 90 day Hematopoietic : WBC great 3,000/mm3 OR Absolute granulocyte count great 1,500/mm3 OR Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.1 mg/dL Lipids great 1.5 time normal Renal : Creatinine great 1.6 mg/dL Cardiovascular : No congestive heart failure No significant arrhythmia No complete bundle branch block Pulmonary : No serious concurrent pulmonary illness Other : No recent uncontrolled bleeding No serous effusion No history autoimmune disease No control uncontrolled active infection No seizure disorder compromise CNS function No secondary gastrointestinal dysfunction could interfere drug absorption No psychological condition would preclude participation consent No second malignancy except basal cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy Chemotherapy : No prior chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : At least 3 month since irradiation target lesion Subsequent progression new lesion require No concurrent radiotherapy Surgery : Prior nephrectomy require No concurrent surgery Other : No concurrent tetracycline hepatotoxic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>